Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

Key PointsTeva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year.

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。